Search results
Showing 76 to 90 of 1359 results for patients and public
Somapacitan for treating growth hormone deficiency in children [ID6178]
In development [GID-TA11153] Expected publication date: TBC
In development [GID-TA11220] Expected publication date: 17 July 2024
In development [GID-TA11221] Expected publication date: 11 September 2024
Relugolix for treating hormone-sensitive prostate cancer [ID6187]
In development [GID-TA11141] Expected publication date: TBC
In development [GID-TA11370] Expected publication date: 16 October 2024
In development [GID-TA11371] Expected publication date: 11 September 2024
Elafibranor for treating primary biliary cholangitis [ID6331]
In development [GID-TA11378] Expected publication date: TBC
Awaiting development [GID-TA11398] Expected publication date: 13 November 2024
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
In development [GID-TA10948] Expected publication date: 26 June 2024
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
In development [GID-TA10733] Expected publication date: TBC
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]
In development [GID-TA11389] Expected publication date: 12 June 2024
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]
In development [GID-TA11392] Expected publication date: 14 August 2024
In development [GID-TA11090] Expected publication date: TBC